5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

Therapeutic Areas

Nervous System DiseasesNeoplasmsImmune System Diseases+ [5]

Active Indication

Depressive Disorder, MajorDepressive Disorder, Treatment-ResistantPeripheral Nervous System Diseases+ [34]

Inactive Indication

AmnesiaBody Dysmorphic DisordersFragile X Syndrome+ [3]

Originator Organization-

Active Organization

Usona Institute

Avextra Pharma GmbH

Incannex Healthcare, Inc.

+ [32]

Inactive Organization

KGK Science, Inc.Halucenex Life Sciences, Inc.

Beckley Psytech Ltd.

+ [2]

License Organization

Revive Therapeutics Ltd.

Psyence Biomedical Ltd.

Psirenity

+ [17]

Drug Highest PhasePhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom)

Structure/Sequence

Molecular FormulaC12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS Registry520-52-5

291

Clinical Trials associated with Psilocybin

NCT06005662

/ SuspendedPhase 2IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Start Date01 Apr 2027

Sponsor / Collaborator

The Johns Hopkins University

NCT07226232

/ Not yet recruitingPhase 3IIT

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

Start Date01 Jun 2026

Sponsor / Collaborator

VA Office of Research and Development

NCT07227909

/ Not yet recruitingPhase 2IIT

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.

Start Date04 May 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Psilocybin

100 Translational Medicine associated with Psilocybin

100 Patents (Medical) associated with Psilocybin

2,482

Literatures (Medical) associated with Psilocybin

01 Feb 2026·JOURNAL OF AFFECTIVE DISORDERS

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Article

Author: Ibrahim, Maya ; Meyer, Thomas D ; Fávaro-Pereira, Leonardo ; Soares, Jair C ; Vale, Lauren N

In recent years psychedelics have gained popularity and potential promise in the field of mental health, but for patients diagnosed with bipolar disorder (BD), fears of emerging manic or psychotic symptoms have caused investigators to exclude them from psychedelic research. In this observational study, we explore the motivations, expectations, and personality characteristics of individuals with BD who have either used (i.e., experimenters) a classic psychedelic (i.e., psilocybin, LSD) or were considering using (i.e., contemplators) in the near future. We compared so-called experimenters to contemplators across various sociodemographic, psychological, and mental health variables. The groups did not differ in socio-demographic variables or mental health, however, experimenters demonstrated more positive attitudes towards psychedelics and more 'openness to experience.' Furthermore, certain motives for use were more strongly endorsed while contemplators expressed concerns about potential negative effects and outcomes. These findings highlight that previous psychedelic experience is associated with more positive perceptions and motivations for use, which might have also been shaped by the actual experience. While we do not advocate for unsupervised use of psychedelics outside of a clinical setting, the study provides some information what areas need to be discussed with individuals with BD who contemplate using psychedelics, even in the context of a clinical trial.

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Corrigendum to “The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression” [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]

Author: Feifel, David ; Malievskaia, Ekaterina ; Páleníček, Tomáš ; Meyer, Thomas D ; Chai-Rees, Jamie ; Somers, Metten ; Mistry, Sunil ; Young, Matthew B ; DeBattista, Charles ; Marwood, Lindsey ; Schoevers, Robert A ; Repantis, Dimitris ; Zisook, Sidney ; Aaronson, Scott T ; Croal, Megan ; Carhart-Harris, Robin ; Wahba, Mourad ; Nowakowska, Ania ; Hellerstein, David J ; Licht, Rasmus W ; Teoh, Emma ; Young, Allan H ; Simmons, Hollie ; Dunlop, Boadie W ; Kelly, John R ; Goodwin, Guy M ; Tsai, Joyce ; Williams, Sam ; Husain, Muhammad I ; Kirlic, Namik ; Alvarez, Oscar

01 Dec 2025·Current Pain and Headache Reports

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management

Review

Author: Strand, Natalie H ; Gomez, Diego ; Leathem, James ; Viswanath, Omar ; Whitney, Madeline ; Johnson, Brooks ; Attanti, Sumedha ; Maloney, Jillian ; Misra, Lopa ; Dunn, Tyler ; Emami, Eric

PURPOSE OF REVIEW:

Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.

RECENT FINDINGS:

These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.

1,051

News (Medical) associated with Psilocybin

03 Dec 2025

·www.prnewswire.com

Benuvia Operations Announces Strategic Partnership with Cannovation Clinical Research Partners to Deliver Fully Integrated Solutions for Controlled-Substance Therapeutics

ROUND ROCK, Texas, Dec. 3, 2025 /PRNewswire/ -- Benuvia Operations, LLC (Benuvia), a global contract development and manufacturing organization, today announced a strategic partnership with Cannovation Clinical Research Partners (CCRP), a global consultancy focused on cannabinoid and psychedelic therapeutic programs. Together, the organizations will create the industry's first fully integrated manufacturing and contract research organization (CRO) platform dedicated to Schedule I–V substances. The collaboration combines Benuvia's end-to-end capabilities in controlled-substance manufacturing, analytical testing, and CMC development with CCRP's expertise in preclinical and clinical research, regulatory strategy, and global trial execution. Through this partnership, pharmaceutical and biotech clinical trial sponsors gain a single, compliant pathway from early-stage development through commercialization for cannabinoid, psychedelic, and novel CNS therapeutics. "Benuvia has spent years building a scalable, compliant, and highly specialized manufacturing platform for controlled-substance innovation," said Terry Novak, CEO of Benuvia. "Partnering with CCRP allows us to align GMP production with coordinated clinical and regulatory execution, eliminating many of the barriers that slow development and improving the speed and efficiency with which sponsors can advance these important medicines." An Integrated Pathway from Discovery to Commercialization Historically, companies developing controlled-substance drugs have been forced to work with separate vendors for preclinical studies, clinical trials, regulatory support, and GMP manufacturing—creating delays, redundancies, and regulatory friction. Through this partnership, sponsors gain: Streamlined IND-to-trial transitions supported by aligned regulatory and operational oversight More efficient timelines through reduced vendor fragmentation and harmonized compliance standards Access to global clinical trial networks spanning North America, Europe, and Latin America Fully DEA-licensed Schedule I–V manufacturing for compounds including psilocybin, LSD, DMT, and additional emerging CNS therapeutics Comprehensive commercialization support to accelerate the safe, compliant delivery of new medicines to patients Accelerating Innovation in Psychedelics, Cannabinoids, and Novel Therapeutics As research into psychedelic and cannabinoid-based CNS treatments accelerates—addressing conditions such as depression, PTSD, and substance-use disorders—demand for reliable, compliant, and highly specialized infrastructure continues to rise. This strategic partnership positions Benuvia and CCRP at the forefront of a market that is expanding globally and evolving rapidly in both scientific and regulatory complexity. "This collaboration underscores our shared mission to improve global healthcare through the responsible development and commercialization of controlled-substance therapeutics," added Lisa Rich-Milan, CEO of CCRP. "By uniting manufacturing, regulatory, and clinical operations within a single coordinated platform, we will be able to offer sponsors a responsible, efficient, and globally accessible pathway for advancing next-generation medicines." About Benuvia Operations, LLC Benuvia Operations, LLC is a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier servicing pharmaceutical and biotech companies. The company provides development and manufacturing services for small-molecule APIs and finished dosage products with extensive experience with cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000 square foot best-in-class manufacturing facility in Round Rock, Texas that can safely and securely handle Schedule I-V controlled substances products, offering comprehensive solutions for companies throughout the entire drug development lifecycle - from API synthesis, clinical trial supply, through commercial production. Learn more at . Forward Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "anticipate', "believe", "could", "estimate", "upcoming", "expect", "intend", "may", "plan", "redirect", "project", "will", and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements should be considered together with the risks and uncertainties discussed in our filings with the Securities and Exchange Commission at . These forward-looking statements are based on information are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law. Contacts For Benuvia Operations, LLC: Arijan Limani, Business Development [email protected] (319) 444-0090 For CCRP: Lisa Rich-Milan, CEO [email protected] (678) 310-8284 SOURCE Benuvia Operations, LLC 21% more press release views with Request a Demo

Clinical Study

26 Nov 2025

·www.globenewswire.com

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

First publicly listed company to actively investigate psilocybin’s potential impact on longevity Nov. 25, 2025 -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first – and currently the only – publicly listed company to investigate psilocybin’s potential impact on biological markers associated with aging and longevity. A successful trial could redefine human longevity and transform the future of aging. Longevity science is gaining unprecedented global attention, driven by rapidly aging populations, escalating healthcare costs, and the visibility of figures like Bryan Johnson, who has openly explored both psychedelic therapies and longevity optimization. Simultaneously, scientific literature continues to build support for the intersection of psychedelics and aging biology. Recent preclinical research has shown that psilocin, psilocybin’s active metabolite, extended survival in aged mouse models and increased the lifespan of human skin and lung cells by more than 50 per cent (Source). Additional studies suggest psilocybin may modulate cellular aging by reducing oxidative stress, preserving telomere length, enhancing neuroplasticity, and activating key longevity-associated pathways (Source). Working closely with an academic neuroscience faculty, Psyence BioMed is developing an accelerated preclinical protocol designed to evaluate whether psilocybin influences biological mechanisms tied to aging. The study will examine biomarkers related to cellular stress, inflammation, mitochondrial function, and behavioural indicators associated with healthspan and lifespan. The Company has commenced the project, with full acceleration anticipated early in the new year following ethics approval. The research will be conducted under the leadership of Dr. Tanya Calvey, PhD, an internationally recognized neuroscientist specializing in translational neuropsychopharmacology. Dr. Calvey’s work bridges human neuroimaging, molecular biology, and neurohistology to explore how psychoactive compounds influence long-term brain health and cellular resilience. “The scientific community is only beginning to uncover the potential links between psychedelics and longevity,” said Dr. Tanya Calvey. “Psilocybin modulates inflammation, neural connectivity, and cellular stress responses – all central to how we understand aging biology. The collaboration with Psyence BioMed enables us to rigorously investigate these mechanisms and generate evidence that could guide future human studies.” “Longevity is quickly emerging as one of the most important global health frontiers,” said Aufrichtig. “With public influencers like Bryan Johnson elevating longevity science and exploring psychedelic-assisted interventions, there is tremendous interest in understanding how psilocybin may influence biological aging. As the first publicly listed company actively pursuing this research, Psyence BioMed is positioned at the forefront of an entirely new therapeutic arena. This longevity initiative complements Psyence BioMed’s ongoing clinical development programs, including its psilocybin-assisted therapy trial for existential distress in palliative care patients in Australia. Together, these programs advance the Company’s mission to explore the full therapeutic potential of psilocybin and ibogaine across multiple dimensions of human health – from mental wellness to long-term biological wellbeing. Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

20 Nov 2025

·www.einpresswire.com

Institute for Integrative Therapies Selected as a Clinical Trial Site for Cybin’s EMBRACE and EXTEND Psilocin Studies

EDEN PRAIRIE, MN, UNITED STATES, November 20, 2025 / EINPresswire.com / -- The Institute for Integrative Therapies (IIT), Minnesota’s leading psychedelic medicine clinic, is proud to announce its official selection as a clinical trial site for Cybin’s EMBRACE and EXTEND studies—two groundbreaking clinical trials evaluating psilocin-based therapeutics for the treatment of Major Depressive Disorder (MDD). Cybin, a clinical-stage publicly traded company developing next-generation psychedelic-derived mental health therapies, selected IIT as one of its U.S. research partners due to IIT’s established expertise, rigorous clinical infrastructure, and track record of excellence in psychedelic medicine interventions. A Major Milestone for Minnesota’s Psychedelic Research Landscape This selection further solidifies IIT as one of the premier destinations for psychedelic research in the Midwest. IIT was the first clinic of its kind in Minnesota and continues to lead the region in delivering innovative, evidence-based psychedelic therapies while contributing to the national research ecosystem. “With the addition of Cybin’s EMBRACE and EXTEND trials, IIT is helping bring the next generation of psychedelic medicines to patients who desperately need new options,” said Manoj Doss, DO, Founder and CEO of IIT and Principal Investigator for the Cybin EMBRACE and EXTEND studies. “We are honored to partner with Cybin in advancing the science and expanding access to modern, transformative care.” About the EMBRACE and EXTEND Studies Cybin’s EMBRACE and EXTEND programs investigate the safety, efficacy, and durability of psilocin-based treatments for individuals living with Major Depressive Disorder. These studies are part of Cybin’s broader mission to create fast-acting, scalable, more predictable psychedelic therapeutics suitable for real-world clinical practice. Enrollment is expected to begin in February 2026 at IIT’s Eden Prairie research clinic, with opportunities for eligible individuals across Minnesota. Strengthening IIT’s Expanding Research Portfolio “We started IIT as a first-of-its-kind clinic in Minnesota, committed to bringing safe, ethical, and effective psychedelic medicine to our community,” said Ranji Varghese, MD, Chief Medical Officer at IIT and Principal Investigator for the COMPASS Pathways psilocybin study. “These partnerships represent the next chapter—one that will help launch a new wave of therapies in the coming years.” Call for Local Clinician Partnership As IIT prepares to launch the Cybin trials, the team is seeking to collaborate with clinicians, therapists, mental health professionals, and medical providers across the Twin Cities and the Midwest who may have patients appropriate for referral. Lunch-and-learn sessions with Dr. Doss and Dr. Varghese will be available for organizations wanting to learn more. About the Institute for Integrative Therapies The Institute for Integrative Therapies (IIT), located in Eden Prairie, Minnesota, is a pioneering clinic specializing in psychedelic medicine, clinical research, and integrative mental health. Founded by Dr. Manoj Doss, IIT combines clinical excellence, compassionate care, and rigorous research to expand access to innovative treatments for depression, anxiety, trauma, and chronic mental health conditions. Andrea Doss Institute for Integrative Therapies email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Study

100 Deals associated with Psilocybin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Psilocybin	-	DB11664

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 3	United States	Usona Institute	13 Mar 2024
Depressive Disorder, Treatment-Resistant	Phase 3	United States	Compass Pathways Plc	19 Jan 2023
Peripheral Nervous System Diseases	Phase 2	United States	The University of Texas MD Anderson Cancer Center	04 May 2026
Stimulant abuse	Phase 2	-	Filament Health Corp.	01 Jan 2025
Opioid abuse	Phase 2	-	Filament Health Corp.	01 Dec 2024
Advanced cancer	Phase 2	United States	The University of Texas MD Anderson Cancer Center	16 Apr 2024
Irritable Bowel Syndrome	Phase 2	United States	Tryp Therapeutics, Inc.	17 Jan 2024
Borderline Personality Disorder	Phase 2	United States	Usona Institute	01 Nov 2023
Neoplasms	Phase 2	United States	Sunstone Medical LLC	23 Oct 2023
Fibromyalgia	Phase 2	United States	University of Michigan	27 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04950608 (PATH, CTgov)	Phase 2	Disease Progression \| Advanced cancer	15	Psilocybin	kwmngecllz = bhpzvcugfh vlooywtmbo (enzajqtoup, hlkhgsrqvq - utnujltabe) View more	-	02 Sep 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Psilocybin (Psilocybin)	jjjbjovwwo(evhcdzgjgf) = lwfubyatml pjuhraqeyq (btgoamanii, .11731) View more	-	27 Jun 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Niacin (Niacin)	jjjbjovwwo(evhcdzgjgf) = oefavutxtd pjuhraqeyq (btgoamanii, .04398) View more	-	27 Jun 2025
NCT05312151 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	22	Psilocybin	yedcgvllyg = lujbpovtwr yqvebcnzpe (bhwdkatzwg, vdmpvbvrvb - tsfxscfjov) View more	-	13 Jun 2025
NCT05847686 (CTgov)	Phase 1/2	Neoplasm Metastasis \| Metastatic Solid Tumor \| Hematologic Neoplasms ... View more	55	Counseling+Psilocybin	mvbghjqfws = rbdxjklquk qdbsjgyzbe (bgpwhapugh, mnijyvjbpu - ukafvsoqkl) View more	-	30 Apr 2025
NCT05128162 (CTgov)	Phase 2	Fibromyalgia	17	Psilocybin	jgkqlhnqks(esxryzqbid) = bkplyfwjia ahcmrkmyrg (pyqhzkuihy, ftkqrbyafl - hhrshsypwp) View more	-	16 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Psilocybin (25 mg)	sxlukfgsxs(piwdfqwyul) = invcjqvsgn lrpvwpwenh (hyamqmruyy, 14.31 - 19.29) View more	Negative	01 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Placebo (mannitol)	sxlukfgsxs(piwdfqwyul) = vojvzahnpl lrpvwpwenh (hyamqmruyy, 10.97 - 16.63) View more	Negative	01 Apr 2025
NCT05163496 (CTgov)	Phase 3	Post Acute COVID 19 Syndrome \| Burnout, Professional \| Stress Disorders, Post-Traumatic	30	Psilocybin (Psilocybin Arm)	kwfkazaslh(ngboabriad) = zvjtjvgxaw nfuivqyrnt (kmatuddkqy, 7.84) View more	-	18 Mar 2025
NCT05163496 (CTgov)	Phase 3		30	Active placebo (Placebo)	kwfkazaslh(ngboabriad) = yrxnknfcdt nfuivqyrnt (kmatuddkqy, 7.32) View more	-	18 Mar 2025
NCT04718792 (Company_Website \| Pubmed) Manual	Phase 2	Alcohol Use Disorder	10	PEX010	ybjdcnzaoa(iscwozljat) = xramdtzmfx nrvdyyhxgp (jqzchnekgf, −61.1 - −13.9) View more	Positive	17 Mar 2025
NCT04433858 (Pubmed \| J Affect Disord)	Phase 2	Depressive Disorder, Treatment-Resistant	15	Psilocybin 25 mg	uabjkiqxiy(grzrhsjfkt) = ldeazypdwq zbjdswzbwt (fombhrckgn ) View more	Positive	01 Jan 2025
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Placebo (Psilocybin)	azabksumzy(tlpnosbxhv) = xmkdczdjek ptvoiuxzjx (blqjqgegge, 0.45) View more	-	24 Oct 2024
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	Phase 2	Depressive Disorder, Major	59	Escitalopram+Psilocybin (Escitalopram)	azabksumzy(tlpnosbxhv) = ofiedpjoqo ptvoiuxzjx (blqjqgegge, 0.62) View more	-	24 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis